NCT03477929 (IVF) is a Phase 4 clinical trial of Ganirelix Acetate in Infertility/Sterility, sponsored by Università degli Studi 'G. d'Annunzio' Chieti e Pescara.

Who is sponsoring NCT03477929?

NCT03477929 is sponsored by Università degli Studi 'G. d'Annunzio' Chieti e Pescara.

What drugs are being tested in NCT03477929?

Interventions in NCT03477929: Ganirelix Acetate, Cetrorelix Acetate.

What condition does NCT03477929 study?

NCT03477929 studies Infertility/Sterility.

Is NCT03477929 still recruiting?

NCT03477929 is currently status unknown. Last updated 27 March 2018.

Last reviewed 2018-03-27 · How we verify

NCT03477929: IVF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cetrorelix and Ganirelix Flexible Protocol for (IVF)

Status unknown Phase 4 Last updated 27 March 2018

What this trial tests

Phase 4 trial testing Ganirelix Acetate in Infertility/Sterility in 100 participants. Status unknown.

Timeline

15 November 2017

Primary endpoint
15 December 2018

15 January 2019

Quick facts

Lead sponsor	Università degli Studi 'G. d'Annunzio' Chieti e Pescara
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	15 November 2017
Primary completion	15 December 2018
Estimated completion	15 January 2019
Sites	1 location across Italy

Drugs / interventions tested

Ganirelix Acetate (GANIRELIX) — full drug profile →
Cetrorelix Acetate — full drug profile →

Conditions studied

Infertility/Sterility — all drugs for Infertility/Sterility →

Sponsor

Università degli Studi 'G. d'Annunzio' Chieti e Pescara

Who can join

Adults 18 to 39, female only, with Infertility/Sterility. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Recombinant gonadotropins are currently used for ovarian stimulation in women undergoing to IVF for infertility. Recently new flexible protocols have been introduced: the "single dose" and "multiple dose" protocol. The single dose protocol is performed just using Cetrorelix by the administration of a single injection of Cetrorelix 3 mg subcutaneous when the lead follicle is ≥ 14 mm. The multiple dose protocol consider the daily administration of Cetrorelix 0.25 mg subcutaneous or Ganirelix 0.25 mg subcutaneous when the lead follicle is ≥ 14 mm and until the realization of hCG criteriaThere are few data from letterature about the comparison of the efficacy in pitituary suppression and pregnancy outcome of Ganirelix and Cetrorelix. Objective: to compare the efficacy in pituitary gonadotropin suppression and IVF outcome of multiple dose flexible gonadotrophin-releasing hormone (GnRH) antagonist administration according to follicular size using daily injection of Cetrorelix or Ganirelix. Interventions : patients are randomly assigned in to Cetrorelix acetate group or Ganirelix acetate group. Multiple dose of Cetrorelix acetate (0.25 mg) or multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met.Oocyte maturation trigger is performed by the administration of subcutaneous r-hCG (250 μg) or of intramuscular hCG (10,000 IU). After 36 hour transvaginal oocyte retrieval is performed followed by ICSI and embrio transfer (72 hours later).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ganirelix Acetate

Trials testing the same drug.

NCT05954962 — Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation. · Phase 4 · completed
NCT04265053 — Human Cerebral Blood Flow Regulation · EARLY_PHASE1 · completed
NCT04654741 — The Rate of Embryo Euploidy in Progestin-primed Ovarian Stimulation Cycles · Phase 4 · unknown

Other Università degli Studi 'G. d'Annunzio' Chieti e Pescara trials

Trials by the same sponsor.

NCT07006194 — Nicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associ · NA · not yet recruiting
NCT06533943 — Blue-green Space Physical Activity: the "Parco Del Mare" Study · NA · recruiting
NCT04412941 — Respiratory Rehabilitation in Obstructive Sleep Apneas · NA · completed
NCT03523364 — Survival Rate of All Ceramic Restorations Treated With Air-Water-Blasting Protocol · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03477929 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Università degli Studi 'G. d'Annunzio' Chieti e Pescara
Last refreshed: 27 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03477929.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing